-
公开(公告)号：US10154995B2
公开(公告)日：2018-12-18
申请号：US15684733
申请日：2017-08-23
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: A61K31/506 , C07D417/14 , C07D405/14 , C07D403/04 , C07D401/14 , C07D471/04 , C07D403/14 , A61K31/4439 , A61K31/444 , A61K45/06
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US09763942B2
公开(公告)日：2017-09-19
申请号：US15197479
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: C07D403/14 , C07D471/04 , C07D417/14 , C07D403/04 , C07D401/14 , A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D405/14
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US20160303126A1
公开(公告)日：2016-10-20
申请号：US15197479
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: A61K31/506 , C07D403/14 , C07D471/04 , A61K31/4439 , C07D417/14 , C07D403/04 , C07D401/14 , A61K31/444 , A61K45/06 , C07D405/14
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
公开(公告)号：US20160304519A1
公开(公告)日：2016-10-20
申请号：US15197445
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC: C07D471/04 , A61K31/5377 , A61K31/55 , A61K31/444 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/506
CPC classification number: C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
Abstract translation: 提供式I化合物或其立体异构体，互变异构体或其药学上可接受的盐，其可用于治疗疾病。 公开了使用式I化合物或其立体异构体，互变异构体或其药学上可接受的盐在体外，原位和体内诊断，预防或治疗这些疾病或相关病理状况的方法。
-
公开(公告)号：US20170348310A1
公开(公告)日：2017-12-07
申请号：US15684733
申请日：2017-08-23
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , Indrani W. Gunawardana , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Tony P. Tang , Allen A. Thomas , Jacob Schwarz , Jane Schmidt , Lewis Gazzard , Huifen Chen
IPC: A61K31/506 , C07D417/14 , C07D405/14 , C07D403/04 , A61K31/4439 , C07D401/14 , A61K45/06 , A61K31/444 , C07D471/04 , C07D403/14
CPC classification number: A61K31/506 , A61K31/4439 , A61K31/444 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D417/14 , C07D471/04
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed.
-
Patent Agency Ranking
公开(公告)号：US09670208B2
公开(公告)日：2017-06-06
申请号：US15197445
申请日：2016-06-29
Applicant: Array BioPharma Inc. , Genentech, Inc.
Inventor： James F. Blake , Adam Cook , John Gaudino , Indrani W. Gunawardana , Erik James Hicken , Kevin W. Hunt , Michael Lyon , Andrew T. Metcalf , Peter J. Mohr , David A. Moreno , Brad Newhouse , Li Ren , Jacob Schwarz , Huifen Chen , Lewis Gazzard , Jane Schmidt , Steve Do
IPC: C07D471/04 , A61K45/06 , A61K31/5377 , A61K31/506 , A61K31/444 , C07D487/04 , C07D519/00 , A61K31/55
CPC classification number: C07D471/04 , A61K31/444 , A61K31/506 , A61K31/5377 , A61K31/55 , A61K45/06 , C07D487/04 , C07D519/00
Abstract: Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed.
-
![SUBSTITUTED N-(lH-INDAZOL-4-YL)IMIDAZO[l,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS](/abs-image/US/2018/03/29/US20180086758A1/abs.jpg.150x150.jpg)
7.发明申请公开(公告)号：US20180086758A1
公开(公告)日：2018-03-29
申请号：US15717700
申请日：2017-09-27
Applicant: ARRAY BIOPHARMA INC.
Inventor： Mark Laurence Boys , Robert Kirk DeLisle , Erik James Hicken , April L. Kennedy , David A. Mareska , Fredrik P. Marmsäter , Mark C. Munson , Brad Newhouse , Bryson Rast , James P. Rizzi , Martha E. Rodriguez , George T. Topalov , Qian Zhao
IPC: C07D471/04 , A61K31/496 , A61K45/06
Abstract: Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R1, R2, R3, R4, R5 and R6 have the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.
-
公开(公告)号：US20230077225A1
公开(公告)日：2023-03-09
申请号：US17869575
申请日：2022-07-20
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Xiaolun Wang , Aaron Craig Burns , James Gail Christensen , John Michael Ketcham , John David Lawson , Matthew Arnold Marx , Christopher Ronald Smith , Shelley Allen , James F. Blake , Mark Joseph Chicarelli , Joshua Ryan Dahlke , Donghua Dai , Jay Bradford Fell , John Peter Fischer , Macedonio J. Mejia , Brad Newhouse , Phong Nguyen , Jacob Matthew O'Leary , Spencer Pajk , Martha E. Rodriguez , Pavel Savechenkov , Tony P. Tang , Guy P.A. Vigers , Qian Zhao , Dean Russell Kahn , John Gaudino , Michael Christopher Hilton
IPC: C07D519/00
Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
公开(公告)号：US10647715B2
公开(公告)日：2020-05-12
申请号：US16412091
申请日：2019-05-14
Applicant: Mirati Therapeutics, Inc. , Array BioPharma Inc.
Inventor： Matthew Arnold Marx , Thomas P. Bobinski , Aaron Craig Burns , John Gaudino , Julia Haas , John Michael Ketcham , John David Lawson , Brad Newhouse , Spencer Pajk , Christopher Ronald Smith , Tony P. Tang
IPC: C07D471/04 , A61P35/00 , C07D519/00
Abstract: The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.
-
10.发明申请N-(ARYLALKYL)-N'-PYRAZOLYL-UREA, THIOUREA, GUANIDINE AND CYANOGUANIDINE COMPOUNDS AS TRKA KINASE INHIBITORS 有权作为TRKA激酶抑制剂的N-（ARYLALKYL）-N'-吡唑并 - 尿素，硫脲，胍和氰基胍化合物公开(公告)号：US20160272592A1
公开(公告)日：2016-09-22
申请号：US14442576
申请日：2013-11-12
Applicant: ARRAY BIOPHARMA INC.
Inventor： James F. Blake , Barbara J. Brandhuber , Julia Haas , Brad Newhouse , Allen A. Thomas , Shannon L. Winski
IPC: C07D231/52 , C07D401/04 , C07D405/14 , C07D401/14 , C07D231/54 , C07D453/02 , C07D495/04 , C07D413/12 , C07D401/12 , C07D403/12 , C07D405/12 , C07D403/04 , C07D231/40
CPC classification number: C07D231/52 , C07D231/38 , C07D231/40 , C07D231/54 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/12 , C07D405/14 , C07D413/12 , C07D453/02 , C07D495/04
Abstract: Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome.
Abstract translation: 式I或其立体异构体，互变异构体或其药学上可接受的盐，溶剂合物或前药的化合物，其中环A，环C，X，R a，R b，R c，R d和n如本文所定义，是TrkA激酶的抑制剂，并且是有用的 治疗可用TrkA激酶抑制剂如疼痛，癌症，炎症/炎性疾病，神经变性疾病，某些感染性疾病，干燥综合征，子宫内膜异位症，糖尿病性周围神经病变，前列腺炎或骨盆疼痛综合征治疗的疾病。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.023 seconds)
